Hsd17b13-KO Mouse
一般名
Hsd17b13-KO
製品ID
S-KO-07421
背景情報
C57BL/6NCya
系統ID
KOCMP-243168-Hsd17b13-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Hsd17b13-KO Mouse（カタログ番号S-KO-07421）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Hsd17b13-KO
系統ID
KOCMP-243168-Hsd17b13-B6N-VA
遺伝子名
製品ID
S-KO-07421
遺伝子別名
Pan1b, PAN1B-like
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 5
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000048118
NCBIトランスクリプトID
NM_198030
ターゲット領域
Exon 2~6
有効領域の大きさ
~6.9 kb
遺伝子研究の概要
HSD17B13, hydroxysteroid 17-β dehydrogenase family 13, is a liver-specific, lipid droplet-associated protein [3,5,8]. It has enzymatic pathways involving steroids, pro-inflammatory lipid mediators and retinol [8]. The 17β-Hydroxysteroid dehydrogenases (HSD17Bs) family, to which HSD17B13 belongs, is mainly involved in sex hormone metabolism, and some members also play roles in cholesterol and fatty acid metabolism [3]. Genetic models, such as gene knockout in mice, are valuable for studying its functions.
In mice, knockdown of Hsd17b13 protects against liver fibrosis in non-alcoholic steatohepatitis, associated with decreased pyrimidine catabolism at the level of dihydropyrimidine dehydrogenase [2]. Also, hepatic overexpression of HSD17B13 in mice promotes lipid accumulation in the liver [3]. The rs72613567-TA variant in HSD17B13, which leads to a loss-of-function, is associated with reduced risk of chronic liver diseases in humans and mitigates liver injury in mouse models [4]. Adeno-associated viral-mediated xeno-expression of human HSD17B13 exacerbates western diet/carbon tetrachloride-induced liver inflammation in Hsd17b13-/-mice [7].
In conclusion, HSD17B13 plays a role in hepatic lipid homeostasis and liver inflammation. Loss-of-function models, including gene knockout in mice, have revealed its contribution to the development of non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and chronic liver inflammation. These findings suggest HSD17B13 could be a potential therapeutic target for treating related liver diseases [1,2,3,4,5,6,7,8,9].
References:
1. Zhang, Hai-Bo, Su, Wen, Xu, Hu, Zhang, Xiao-Yan, Guan, You-Fei. 2022. HSD17B13: A Potential Therapeutic Target for NAFLD. In Frontiers in molecular biosciences, 8, 824776. doi:10.3389/fmolb.2021.824776. https://pubmed.ncbi.nlm.nih.gov/35071330/
2. Luukkonen, Panu K, Sakuma, Ikki, Gaspar, Rafael C, Petersen, Kitt Falk, Shulman, Gerald I. 2023. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. In Proceedings of the National Academy of Sciences of the United States of America, 120, e2217543120. doi:10.1073/pnas.2217543120. https://pubmed.ncbi.nlm.nih.gov/36669104/
3. Su, Wen, Mao, Zhuo, Liu, Yiao, Gustafsson, Jan-Ake, Guan, Youfei. 2018. Role of HSD17B13 in the liver physiology and pathophysiology. In Molecular and cellular endocrinology, 489, 119-125. doi:10.1016/j.mce.2018.10.014. https://pubmed.ncbi.nlm.nih.gov/30365983/
4. Abul-Husn, Noura S, Cheng, Xiping, Li, Alexander H, Gromada, Jesper, Dewey, Frederick E. . A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. In The New England journal of medicine, 378, 1096-1106. doi:10.1056/NEJMoa1712191. https://pubmed.ncbi.nlm.nih.gov/29562163/
5. Motomura, Takashi, Amirneni, Sriram, Diaz-Aragon, Ricardo, Florentino, Rodrigo M, Soto-Gutierrez, Alejandro. 2021. Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. In Journal of personalized medicine, 11, . doi:10.3390/jpm11070619. https://pubmed.ncbi.nlm.nih.gov/34208839/
6. Wang, P, Wu, C-X, Li, Y, Shen, N. . HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis. In European review for medical and pharmacological sciences, 24, 8997-9007. doi:10.26355/eurrev_202009_22842. https://pubmed.ncbi.nlm.nih.gov/32964989/
7. Ye, Jing, Huang, Xiyu, Yuan, Manman, Xu, Qiang, Wu, Xingxin. . HSD17B13 liquid-liquid phase separation promotes leukocyte adhesion in chronic liver inflammation. In Journal of molecular cell biology, 16, . doi:10.1093/jmcb/mjae018. https://pubmed.ncbi.nlm.nih.gov/38692847/
8. Amangurbanova, Maral, Huang, Daniel Q, Loomba, Rohit. 2022. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. In Alimentary pharmacology & therapeutics, 57, 37-51. doi:10.1111/apt.17292. https://pubmed.ncbi.nlm.nih.gov/36349732/
9. Stender, Stefan, Romeo, Stefano. . HSD17B13 as a promising therapeutic target against chronic liver disease. In Liver international : official journal of the International Association for the Study of the Liver, 40, 756-757. doi:10.1111/liv.14411. https://pubmed.ncbi.nlm.nih.gov/32255570/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。